Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed as an approved prescription medicine. It is marketed under the brand names Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), and is designed for once-daily subcutaneous administration. Its structure is a modified human GLP-1 analog with a fatty-acid chain that promotes reversible binding to albumin, extending its duration relative to native GLP-1.

As with other agents in this class, the approved, regulated products differ from "research" or "for research use only" versions sold outside pharmacy channels. Such vendor material is not the approved medicine, is not subject to the same quality assurance, and should not be considered interchangeable with a prescribed product.

Liraglutide activates the GLP-1 receptor, reproducing key actions of the incretin hormone GLP-1. Described mechanisms include:

• Enhancing glucose-dependent insulin secretion from the pancreas
• Reducing inappropriate glucagon secretion when glucose is elevated
• Slowing gastric emptying to blunt post-meal glucose spikes
• Acting on central appetite pathways to lower hunger and energy intake

Because its insulin effect is glucose-dependent, the class is associated with a comparatively low intrinsic risk of hypoglycemia, though that risk increases when it is combined with insulin or insulin secretagogues.

In regulated medical practice, liraglutide has been approved (depending on jurisdiction and brand) as an adjunct to diet and exercise for glycemic control in type 2 diabetes, and separately for chronic weight management in individuals meeting defined criteria. The two branded products differ in their approved indications and labeling despite sharing the same active molecule.

Liraglutide is a distinct molecule from semaglutide and dulaglutide, with a different dosing frequency and pharmacokinetic profile. Any real-world use should be directed by a qualified clinician and aligned with local regulations and product labeling.

Liraglutide is not named anywhere on the WADA Prohibited List, and GLP-1 receptor agonists do not have a class entry. Nothing in S0 catches them either: S0 covers substances with "no current approval by any governmental regulatory health authority for human therapeutic use," and liraglutide is an approved medicine in essentially every major jurisdiction.

The more interesting fact is what sits alongside the List. WADA also publishes a Monitoring Program under Article 4.5 of the World Anti-Doping Code, covering "substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport." Item 6 of the 2026 Monitoring Program is "Markers of Semaglutide and Tirzepatide," in and out of competition — the first time incretin drugs have appeared there. Monitoring findings cannot produce an anti-doping rule violation, and liraglutide is not named. But monitoring is how substances typically enter the conversation before a listing decision, and the direction of travel for this drug class is now on the record.

Separately, an athlete using liraglutide for an approved indication may still need to consider therapeutic use documentation in sports with weight categories or body-composition rules, which operate independently of the Prohibited List.

Gastrointestinal effects are the most commonly described, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These are often most pronounced early in use.

Product labeling for this class carries a boxed warning about thyroid C-cell tumors seen in rodent studies, with human relevance uncertain; the class is generally described as contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis and gallbladder-related events, including gallstones, are also discussed, along with injection-site reactions. Contraindications, monitoring, and overall risk–benefit judgments should be made by a prescribing clinician.

Liraglutide's albumin-binding design gives it a half-life supporting once-daily administration, which differs from once-weekly agents in the class. The approved products follow a structured titration approach intended to improve gastrointestinal tolerability.

This page intentionally avoids specific numbers, schedules, or protocols. Concentration, exposure, and titration are governed by the approved product's labeling and by the prescribing clinician. Any decisions about administration belong within that regulated framework.

The approved medicines are supplied as multi-dose prefilled subcutaneous pens. Liraglutide is also a component of at least one approved fixed-ratio combination with basal insulin in some regions, illustrating class interest in complementary co-formulation.

Any structural or catalog listings are organizational and are not endorsements of specific combinations, sourcing, or use cases; vendor "research" material remains distinct from the approved formulations.

Randomized controlled trials have evaluated liraglutide for glycemic control in type 2 diabetes and for weight management, and dedicated cardiovascular outcome research has examined its effects on major cardiovascular events in relevant populations. Additional studies have explored related metabolic endpoints.

Because the evidence base evolves, this is a high-level snapshot rather than a comprehensive or permanently current review. Clinical and personal decisions should rely on up-to-date primary literature, current labeling, and trusted guidelines.

For deeper dives on this peptide, see:

• Liraglutide benefits and areas of interest
• Liraglutide side effects and safety context
• Liraglutide dosing concepts (educational)
• Liraglutide research and evidence overview

Are Victoza and Saxenda the same drug? They contain the same active molecule, liraglutide, but they are separate products with separate labels, indications, and maximum doses. Victoza is indicated as an adjunct to diet and exercise for glycemic control in adults and children aged 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, with dosing titrated to 1.8 mg daily (Victoza prescribing information). Saxenda is indicated for weight reduction and maintenance alongside a reduced-calorie diet and increased physical activity, at a recommended dose of 3 mg daily (Saxenda prescribing information). Both labels state that coadministration with another liraglutide-containing product is not recommended.

Why is liraglutide injected daily rather than weekly? Native GLP-1 has a half-life of only 1.5 to 2 minutes because DPP-4 and neutral endopeptidases degrade it almost immediately. Liraglutide's fatty-acid chain lets it bind reversibly to albumin and resist those enzymes, giving a plasma half-life of approximately 13 hours after subcutaneous injection — long enough for once-daily dosing but well short of the multi-day exposure that supports the weekly agents in the class (Victoza prescribing information).

What did the LEADER trial show? LEADER randomized 9,340 people with type 2 diabetes at high cardiovascular risk to liraglutide or placebo for a median of 3.8 years. The primary composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke was reduced with liraglutide (hazard ratio 0.87, 95% CI 0.78–0.97; p=0.01 for superiority), with lower cardiovascular death (HR 0.78) and lower all-cause death (HR 0.85) (Marso et al., NEJM 2016). That trial is the basis for the cardiovascular risk-reduction wording on the Victoza label.

How much weight loss was seen in the SCALE trial? In the SCALE Obesity and Prediabetes trial, 3,731 adults without type 2 diabetes received liraglutide 3.0 mg or placebo plus lifestyle counseling for 56 weeks. Mean weight loss was 8.4 kg with liraglutide versus 2.8 kg with placebo, and 63.2% versus 27.1% lost at least 5% of body weight (Pi-Sunyer et al., NEJM 2015). Nausea and diarrhea were the most commonly reported adverse effects.

How does liraglutide compare with semaglutide head-to-head? Two randomized comparisons favored semaglutide. In SUSTAIN 10, weekly semaglutide 1.0 mg lowered HbA1c by 1.7% versus 1.0% for daily liraglutide 1.2 mg, and body weight by 5.8 kg versus 1.9 kg, over 30 weeks (Capehorn et al., Diabetes Metab 2020). In STEP 8, which used the weight-management doses in adults with overweight or obesity and no diabetes, weight fell 15.8% with semaglutide 2.4 mg versus 6.4% with liraglutide 3.0 mg at 68 weeks (Rubino et al., JAMA 2022). Neither trial pitted every product at its maximum approved dose, so the margins are specific to the doses compared.

Is there a generic liraglutide? Yes for the diabetes product. On December 23, 2024 the FDA approved the first generic referencing Victoza (liraglutide injection, 18 mg/3 mL), noting that liraglutide was in shortage at the time and that generic applications for drugs in shortage are prioritized (FDA news release). An approved generic is a pharmacy product held to the same standards as the reference drug — which is a different category entirely from material sold online as "research" liraglutide.

Is vendor "research" liraglutide equivalent to the approved product? No. The approved products carry a boxed warning about rodent thyroid C-cell tumors, defined contraindications, and manufacturing oversight that gray-market vials do not. The FDA has publicly warned about unapproved and compounded GLP-1 products, including uncertainty over the identity and quantity of what is in them (FDA statement on unapproved GLP-1 drugs). The trial results summarized above describe the approved medicine and cannot be assumed to transfer to unverified material.